As­traZeneca's Imfinzi fails in lung can­cer tri­al as a monother­a­py to im­prove OS

As­traZeneca can add an­oth­er tri­al to the list of Imfinzi flops.

On Mon­day, the bio­phar­ma an­nounced that its PEARL Phase III tri­al test­ing out its block­buster drug Imfinzi as a monother­a­py for lung can­cer did not hit its pri­ma­ry end­point of over­all sur­vival.

There are no da­ta yet, how­ev­er, and the Big Phar­ma says it will be shared “in due course.”

The PEARL tri­al, con­duct­ed pri­mar­i­ly in Asia, looked at Imfinzi as a po­ten­tial monother­a­py for the treat­ment of pa­tients with Stage IV metasta­t­ic non-small cell lung can­cer with tu­mor cells that ex­pressed 25% or more of the pro­tein PD-L1. The oth­er pri­ma­ry end­point was over­all sur­vival in pa­tients iden­ti­fied as low risk of ear­ly mor­tal­i­ty.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.